Please login to the form below

AMD

This page shows the latest AMD news and features for those working in and with pharma, biotech and healthcare.

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Allergan’ s abicipar matches AMD blockbuster Lucentis in phase III. Bayer's Eylea remains the drug to beat, however. ... Allergan has positive phase III results for a wet age-related macular degeneration (AMD) drug that seems to be at least as good as

Latest news

Joerg Moeller to head Bayer R&D after operational shake-up

The company has suffered a few R&D disappointments of late, however, including the failures of a Regeneron-partnered combination therapy for age-related macular degeneration (AMD) and a drug-device
Regeneron and Bayer drop AMD combination

Regeneron and Bayer drop AMD combination. Abandon plans after disappointing phase II trial results. ... advance the duo into phase III in either AMD or diabetic macular oedema.
Novartis buys two firms in pre-Christmas shopping spree

Those only gathered pace after a late-stage setback for age-related macular degeneration (AMD) therapy Fovista (pegpleranib), which was licensed by the company in 2014 in a deal valued at
Novartis' AMD drug pegpleranib fails phase III programme

or wet forms of AMD provided no additional benefit over Lucentis given alone. ... AMD affects up to 25 million people worldwide and is the leading cause of early blindness in the industrialised world.
Better together?

the treatment of AMD.

More from news
Approximately 24 fully matching, plus 77 partially matching documents found.

Latest Intelligence

30 Women Leaders in UK Healthcare (part 2)

treatments for age-related macular degeneration (AMD).
The good, the bad and the ugly

In the EU, where there’s a high prevalence of AMD, Bayer has enjoyed great success with Eylea - growing revenues by 18% in 2017, ”says Alice Stevens, analyst, cardiovascular and metabolic ... The company plans to launch the highly anticipated
Working with our healthcare system more closely is vital

to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD).
Deal Watch November 2015

The acquisition brings an ophthalmology focus with products for Stargardt's macular degeneration, dry AMD, and myopic macular degeneration. ... 380. Ocata Therapeutics. Astellas Pharma| Laurel. Acquisition - company. Regenerative medicine pipeline focus
Pharma deals during May 2014

Coincidentally two weeks earlier, there was another deal for a product for treating AMD. ... Regeneron also has a time limited first right of negotiation to Avalanche's VEGF agent in phase IIa for AMD.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

Gyroscope Therapeutics appoints CEO

Gyroscope has a unique translational approach to tackling complex diseases such as dry AMD for which there are no therapies today.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Editorial Director – Medical Education (MedComms): Neg

Home based, Chief Medical Writer, Medical Communications: Excellent package

Business Unit Head, Medical Communications, London: Excellent package

Delivery Manager/ Head of Delivery – Executive Search: Neg

Client Services Director - Med Comms: Great salary and bebefits

Home based, Senior Medical Writer, Medical Communications: Excellent package

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Healthcare PR Director: £100, 000 – £120, 000 benefits

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Home based, Editorial Team Leader, Medical Communications: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Account Manager: Competitive salary commensurate with experience

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Client Services Director – Healthcare Advertising - London: Neg

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Subscribe to our email news alerts

PMHub

Add my company

Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....